Trial · NCT06451419
Registered outcomes135
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 40 of 135
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Change in Rey figure from baseline to 24 months | 2 years | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Rey figure test, scoring from 0 to 72 points, meaning lower punctuations altered visuoperception and visual episodic memory. |
| Secondary | Change in Rey figure from baseline to 6 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Rey figure test, scoring from 0 to 72 points, meaning lower punctuations altered visuoperception and visual episodic memory. |
| Secondary | Change in Rey figure from 6 months to 12 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Rey figure test, scoring from 0 to 72 points, meaning lower punctuations altered visuoperception and visual episodic memory. |
| Secondary | Change in Rey figure from 12 months to 18 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Rey figure test, scoring from 0 to 72 points, meaning lower punctuations altered visuoperception and visual episodic memory. |
| Secondary | Change in Rey figure from 18 months to 24 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Rey figure test, scoring from 0 to 72 points, meaning lower punctuations altered visuoperception and visual episodic memory. |
| Secondary | Change in Weschler Memory test from baseline to 24 months | 2 years | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Weschler Memory test, scoring in relation to age with percentiles from 0 to 100, lower percentile meaning a greater memory disturbance. |
| Secondary | Change in Weschler Memory test from baseline to 6 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Weschler Memory test, scoring in relation to age with percentiles from 0 to 100, lower percentile meaning a greater memory disturbance. |
| Secondary | Change in Weschler Memory test from 6 months to 12 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Weschler Memory test, scoring in relation to age with percentiles from 0 to 100, lower percentile meaning a greater memory disturbance. |
| Secondary | Change in Weschler Memory test from 12 months to 18 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Weschler Memory test, scoring in relation to age with percentiles from 0 to 100, lower percentile meaning a greater memory disturbance. |
| Secondary | Change in Weschler Memory test from 18 months to 24 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Weschler Memory test, scoring in relation to age with percentiles from 0 to 100, lower percentile meaning a greater memory disturbance. |
| Secondary | Change in Stroop test from baseline to 24 months | 2 years | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Stroop test with T-scores from 0 to 100, higher scores reflecting better performance and less interference on reading ability. |
| Secondary | Change in Stroop test from baseline to 6 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Stroop test with T-scores from 0 to 100, higher scores reflecting better performance and less interference on reading ability. |
| Secondary | Change in Stroop test from 6 months to 12 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Stroop test with T-scores from 0 to 100, higher scores reflecting better performance and less interference on reading ability. |
| Secondary | Change in Stroop test from 12 months to 18 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Stroop test with T-scores from 0 to 100, higher scores reflecting better performance and less interference on reading ability. |
| Secondary | Change in Stroop test from 18 months to 24 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Stroop test with T-scores from 0 to 100, higher scores reflecting better performance and less interference on reading ability. |
| Secondary | Change in Trail Making Test A from baseline to 24 months | 2 years | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Trail Making Test A, with scores ranging from 0 to 100 seconds, lower scores meaning better performance. |
| Secondary | Change in Trail Making Test B from baseline to 24 months | 2 years | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Trail Making Test B, with scores ranging from 0 to 300 seconds, lower scores meaning better performance. |
| Secondary | Change in Trail Making Test A from baseline to 6 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Trail Making Test A, with scores ranging from 0 to 100 seconds, lower scores meaning better performance. |
| Secondary | Change in Trail Making Test B from baseline to 6 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Trail Making Test A, with scores ranging from 0 to 100 seconds, lower scores meaning better performance. |
| Secondary | Change in Trail Making Test A from 6 months to 12 months | 6 months | To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Trail Making Test B, with scores ranging from 0 to 300 seconds, lower scores meaning better performance. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06451419/registered?page=2